Abstracts tagged "biologic response modifiers"

Abstract Number: 2155 • 2012 ACR/ARHP Annual Meeting
The Annualized Progression of Radiologic Damage in Placebo Arms of Rheumatoid Arthritis Trials Is Much Lower Than the Mean Annual Progression Since Disease Onset
Jean-Marie Berthelot and Celine Cozic, Rheumatology Unit, Nantes University Hospital, Nantes, France
Background/Purpose : A previous meta-analysis by Graudal and Jürgens (Arthritis Rheum. 2010;62:2852–63) challenged the belief that biologics better protect rheumatoid arthritis (RA) from joint destruction…
Abstract Number: 1145 • 2012 ACR/ARHP Annual Meeting
Use of Non-Etanercept Biologics in Children with Juvenile Idiopathic Arthritis: Results From the Biologics for Children with Rheumatic Diseases Study
Lianne Kearsley-Fleet¹, Eileen Baildam², Michael Beresford³, Rebecca Davies⁴, Helen E. Foster⁵, Katy Mowbray¹, Taunton R. Southwood⁶, Wendy Thomson¹ and Kimme L. Hyrich⁷, ¹Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Paediatric Rheumatology, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, ³University of Liverpool, Institute of Translational Medicine (Child Health), Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, ⁴Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁵Institute Cellular Medicine, Musculoskeletal Research Group, Newcastle upon Tyne, United Kingdom, ⁶Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom, ⁷Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom
Background/Purpose: The management of juvenile idiopathic arthritis (JIA) has been revolutionised by the introduction of biologic therapy, although the majority remain unlicensed for children. Until…
Abstract Number: 2093 • 2012 ACR/ARHP Annual Meeting
Rates of Opportunistic Infections Among Rheumatoid Arthritis Patients Switching Biologic Therapy
John Baddley¹, Shuo Yang², Klye Brizendine³, Scott DuVall⁴, Kevin L. Winthrop⁵, Mary J. Burton⁶, Nivedita M. Patkar⁷, Elizabeth S. Delzell⁸, Monika M. Safford⁹, Jasvinder A. Singh¹⁰, Iris E. Navarro¹¹, Grant W. Cannon¹², Ted R. Mikuls¹³, Lang Chen¹¹, Kenneth G. Saag¹⁴, Kimberly Alexander¹⁵, Pavel Napalkov¹⁵, Aaron Kamauu¹⁶ and Jeffrey R. Curtis¹⁷, ¹Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Infectious Disease, Birmingham, AL, ⁴VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, ⁵Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ⁶VA Hospital, Jackson, MS, ⁷Immunology/Rheumatology, Univ of Alabama-Birmingham, Birmingham, AL, ⁸Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁹Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹⁰Department of Medicine, University of Alabama, Tuscaloosa, AL, ¹¹Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹²Division of Rheumatology, George E. Wahlen VA Medical Center, Salt Lake City, UT, ¹³Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ¹⁴Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, ¹⁵Epidemiology, Genentech, Inc., South San Francisco, CA, ¹⁶Anolinx, Bountiful, UT, ¹⁷Rheumatology & Immunology, Univ of Alabama-Birmingham, Birmingham, AL
Background/Purpose: The incidence of opportunistic infections (OIs) in patients on biologics is low, but may approach several cases per 100 person-years (PY). Data on risks…
Abstract Number: 1146 • 2012 ACR/ARHP Annual Meeting
Choice of Systemic JIA Treatment Among Childhood Arthritis and Rheumatology Research Alliance (CARRA) Rheumatologists
Jennifer E. Weiss¹, Esi M. Morgan DeWitt², Timothy Beukelman³, Laura E. Schanberg⁴, Rayfel Schneider⁵ and Yukiko Kimura⁶, ¹Pediatric Rheumatology, Hackensack University Medical Center, Hackensack, NJ, ²Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Pediatrics, Duke University Medical Center, Durham, NC, ⁵Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, Canada, ⁶Pediatric Rheumatology, Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ
Background/Purpose: Despite recent advances in identifying effective treatments for systemic Juvenile Idiopathic Arthritis (sJIA), many pediatric rheumatologists continue to use corticosteroids and methotrexate. The Childhood…
Abstract Number: 2055 • 2012 ACR/ARHP Annual Meeting
TEAM-Managed Care of Biological Patients At A Canadian Centre
Melissa Deamude¹, Dawn Heap², Melanie Kanellos², Debbie Kislinsky³, Kathy Kislinsky¹, Cynthia Mech⁴, Helena Ross¹, Peggy Saldanha³, Lauri Vanstone⁵, Kathleen Brown⁶ and William G. Bensen⁷, ¹Dr. William G. Bensen, Rheumatology Health Team, St. Joseph's Hospital Hamilton, Hamilton, ON, Canada, ²Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ³Dr. William Bensen Rheumatology Clinic, Hamilton, ON, Canada, ⁴Dr. William G. Bensen, Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ⁵Dr. William Bensen Rheumatology Biologic Clinic, Rheumatology Health Team, Hamilton, ON, Canada, ⁶Dr. William Bensen Rheumatology Clinic, Rheumatology Health Team, St. Joseph's Hospital Hamilton, Hamilton, ON, Canada, ⁷Department of Medicine, Division of Rheumatology, St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada
Background/Purpose: Managing complex arthritic patients with biologics is exacting and time consuming. As a result in January 2008 we established a separate biologic clinic with…
Abstract Number: 1004 • 2012 ACR/ARHP Annual Meeting
A Unique Single Nucleotide Polymorphism in the 3’ UTR of the MED29 Gene On Chromosome 19 Is Associated with the Clinical Outcome of Different Biologic Response Modifiers
Susanne Drynda¹, David Leesch², Marietta Gloetzner² and Joern Kekow², ¹Clinic of Rheumatology, Univ of Magdeburg, Clinic of Rheumatology, Vogelsang-Gommern, Germany, ²Clinic of Rheumatology, Univ of Magdeburg, Vogelsang-Gommern, Germany
Background/Purpose: Due to the wide range of highly specific and effective biologic response modifiers that are available today for the treatment of RA it has…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].